Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tango Therapeutics, Inc. on April 10, 2026, with the earliest event reported on the same date. The filing addresses significant changes in the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of new financial officers effective April 15, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. As a clinical-stage biopharmaceutical company reporting a personnel change, this document contains no financial performance data for the period.
Material Changes
The primary material change reported is the restructuring of the Company's financial leadership team:
- Departure: Daniella Beckman will cease serving as Chief Financial Officer, principal accounting officer, and principal financial officer effective April 15, 2026.
- Appointment of CFO: Matthew Gall, MBA, was appointed as Chief Financial Officer and principal financial officer effective April 15, 2026. Mr. Gall previously served as CFO at Kalaris Therapeutics, Inc. (Nov 2025 - Apr 2026) and iTeos Therapeutics, Inc. (Jun 2020 - Aug 2025).
- Appointment of Principal Accounting Officer: Jessica Newcomb, CPA, was appointed as principal accounting officer effective April 15, 2026. Ms. Newcomb is currently the Senior Vice President, Finance at the Company.
Compensation and Equity Arrangements
In connection with his appointment, Matthew Gall entered into an employment agreement with the following terms:
- Base Salary: $540,000 annually.
- Cash Bonus: Target opportunity of 40% of the annual base salary, pro-rated for partial years.
- Stock Options: Option to purchase 240,000 shares under the 2023 Inducement Plan. The exercise price is set at the closing price on May 1, 2026. Vesting is 25% on the one-year anniversary of employment, with the remainder vesting monthly over 36 months.
- Restricted Stock Units (RSUs): Grant of 40,000 shares vesting in three approximately equal annual installments.
Outlook, Risks, and Contingencies
The filing does not contain updated financial guidance, market outlook, or specific risk factors beyond the standard disclosure that the press release furnished as Exhibit 99.1 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the leadership transition (April 15, 2026) and confirm the interim financial reporting structure.
- Review the full Employment Agreement (Exhibit 10.1) for additional terms regarding severance, non-compete clauses, or acceleration provisions not summarized in the 8-K.
- Monitor the stock price on May 1, 2026, to determine the exercise price for Mr. Gall's 240,000 stock options.
- Assess the impact of the CFO departure on the Company's upcoming financial reporting cycles and investor relations strategy.